Occupational exposure to HIV: Experience at a tertiary care center

Journal of Occupational and Environmental Medicine

Volumn 40, Issue 12, 1998, Pages 1102-1109

  Swotinsky, Robert B ^a,c   Steger, Kathleen A ^a,b   Sulis, Carol ^a   Snyder, Sandra ^c   Craven, Donald E ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LAMIVUDINE; ZIDOVUDINE;

ARTICLE; CHEMOPROPHYLAXIS; GASTROINTESTINAL TOXICITY; HEADACHE; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALAISE; MENSTRUAL IRREGULARITY; MYALGIA; NEUROTOXICITY; OCCUPATIONAL EXPOSURE; PREVALENCE; RASH; VERTIGO; VIRUS TRANSMISSION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0032414572     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043764-199812000-00010     Document Type: Article

References (28)

1. CDC. Public Health Service statement on management of occupational exposures to human immunodeficiency virus, including considerations regarding zidovudine postexposure use. MMWR Morb Mortal Wkly Rep. 1990;39(RR-1):1-14.
2. CDC. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood: France, United Kingdom, and United States, January 1988-August 1994. MMWR Morb Mortal Wkly Rep. 1995;44:929-933.
3. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med. 1997; 337:1485-1490.
4. Gerberding JL. Management of occupational exposures to blood-borne viruses. N Engl J Med. 1995;332:444-451.
5. Tokars JI, Marcus R, Culver DH, et al. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. Ann Intern Med. 1993; 118:913-919.
6. CDC. Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR Morb Mortal Wkly Rep. 1996;45:468-472.
7. Yarchoan R, Mitsuya H, Myers C, Broder S. Clinical pharmacology of 3-azido-2,3-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med. 1989;321:726-738.
8. Kitchen VS, Skinner C, Ariyoshi K, et al. Safety and activity of saquinavir in HIV infection. Lancet. 1995;345:952-955.
9. Public Health Service Guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Rep. 1998;47(RR-7):1-28.
10. Donegan SP, Steger KA, Recla L, et al. Seroprevalence of human immunodeficiency virus in parturients at Boston City Hospital: implications for public health and obstetric practice. Am J Obstet Gynecol. 1992;167:622-629.
11. Kleinbaum DG, Kupper LL, Morganstern H. Epidemiologic Research: Principles and Quantitative Methods. Belmont, CA: Lifetime Learning Publications; 1982.
12. Catalano MT. Postexposure prophylaxis implementation issues: programmatic concerns in hospitals. Am J Med. 1997; 102(5B):95-97.
13. L'Ecuyer PB, Fraser VJ. Issues complicating the implementation of postexposure prophylaxis. Am J Med. 1997; 102(5B):90-94.
14. Gerberding JL. Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood exposure: final report from a longitudinal study. J Infect Dis. 1994;170:1410-1417.
15. Ippolito G, Puro V, De Carli G, Italian Study Group on Occupational Risk of HIV Infection. The risk of occupational human immunodeficiency virus infection in health care workers: Italian Multicenter Study. Arch Intern Med. 1993;153: 1451-1458.
16. Sperling RS, Shapiro DE, Coombs R, et al. Maternal viral load, zidovudine treatment, and risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med. 1996; 335:1621-1629.
17. Nguyen BY, Haas DW, Ramirez-Ronda C, et al. A pilot, multicenter, open-label, randomized study to compare the safety and activity of indinavir sulfate (IDV) administered every 8 hours (h) versus 12 h in combination with zidovudine (ZDV) and lamivudine (3TC). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 28-October 1, 1997:I-91.
18. Cardo DM, Campbell S, Srivastava P, and National Surveillance System for Health Care Workers (NaSH). Postexposure prophylaxis after occupational HIV exposure. 35th Annual Meeting, Infectious Diseases Society of America, San Francisco, CA, September 13-16, 1997: 270.
19. Ippolito G, Puro V, and the Italian Registry of Antiretroviral Prophylaxis. Zidovudine toxicity in uninfected health care workers. Am J Med. 1997;102(5B): 58-62.
20. Struble KA, Pratt RD, Gitterman SR. Toxicity of antiretroviral agents. Am J Med. 1997;102(5B):65-67.
21. Food and Drug Administration. Reports of Diabetes and Hyperglycemia in Patients Receiving Protease Inhibitors for the Treatment of Human Immunodeficiency Virus (HIV). [FDA Public Health Advisory.] Rockville, MD: FDA; 1997.
22. McDonald CK, Kuritzkes DR. Human immunodeficiency virus type 1 protease inhibitors. Arch Int Med. 1997;157:951-959.
23. Department of Labor, Occupational Safety and Health Administration. Occupational exposure to bloodborne pathogens: final rule. Fed Regist. 1991; 56(235):64004-64182 (December 6, 1991).
24. Kassler WJ, Haley C, Jones WK, Gerber AR, Kennedy EI, George JR. Performance of a rapid, on-site human immunodeficiency virus antibody assay in a public health setting. J Clin Microbiol. 1995;33:2899-2902.
25. Forst LS, Fletcher B. HIV Prophylaxis for health care workers. J Occup Environ Med. 1997;39:1212-1219.
26. Shelton D. Review of experimental or investigative procedures. Fla Workers Comp Informer. 1997;2:4-5.
27. Tereskerz PM, Pearson RD, Jagger J. Occupational exposure to blood among medical students. N Engl J Med. 1996; 335:1150-1153.
28. Katz MH, Gerberding JL. Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use. N Engl J Med 1997;336:1097-1100.